CVS Health (NYSE:CVS) Price Target Raised to $55.00

CVS Health (NYSE:CVS) had its price target increased by stock analysts at Leerink Partners from $51.00 to $55.00 in a research report issued on Tuesday. The firm currently has a “market perform” rating on the pharmacy operator’s stock. Leerink Partners’ target price would suggest a potential downside of 0.02% from the stock’s previous close.

Other research analysts also recently issued research reports about the stock. Truist Financial reduced their price target on shares of CVS Health from $67.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Deutsche Bank Aktiengesellschaft upgraded CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a research report on Tuesday, December 3rd. Royal Bank of Canada dropped their price target on CVS Health from $68.00 to $58.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Piper Sandler decreased their price objective on CVS Health from $72.00 to $64.00 and set an “overweight” rating on the stock in a report on Monday, November 25th. Finally, TD Cowen upped their target price on shares of CVS Health from $73.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, November 25th. One analyst has rated the stock with a sell rating, six have given a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $67.78.

CVS Health Price Performance

NYSE CVS traded up $0.72 on Tuesday, hitting $55.01. The company had a trading volume of 12,643,705 shares, compared to its average volume of 12,420,613. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. The company’s fifty day moving average price is $50.69 and its 200-day moving average price is $55.95. The company has a market capitalization of $69.23 billion, a PE ratio of 13.96, a PEG ratio of 0.60 and a beta of 0.61. CVS Health has a 12-month low of $43.56 and a 12-month high of $80.75.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CVS. Assetmark Inc. lifted its holdings in shares of CVS Health by 9.7% in the 3rd quarter. Assetmark Inc. now owns 410,001 shares of the pharmacy operator’s stock worth $25,781,000 after acquiring an additional 36,132 shares during the last quarter. TD Private Client Wealth LLC lifted its stake in CVS Health by 28.7% during the third quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator’s stock worth $2,951,000 after purchasing an additional 10,465 shares in the last quarter. Cullinan Associates Inc. boosted its position in shares of CVS Health by 43.8% during the third quarter. Cullinan Associates Inc. now owns 122,682 shares of the pharmacy operator’s stock worth $7,125,000 after buying an additional 37,395 shares during the period. Principal Financial Group Inc. grew its stake in shares of CVS Health by 4.8% in the third quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator’s stock valued at $90,200,000 after buying an additional 66,244 shares in the last quarter. Finally, Sompo Asset Management Co. Ltd. lifted its stake in CVS Health by 8.4% during the 3rd quarter. Sompo Asset Management Co. Ltd. now owns 134,523 shares of the pharmacy operator’s stock worth $8,459,000 after acquiring an additional 10,453 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.